drugset / Trial / NCT01598857

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

NCT01598857 ↗

Phase 2 Withdrawn Anthera Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.

Timeline

Start
2014-12
Primary completion
2015-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Blisibimod Peptide — —